Cargando…

Telomerase Variant A279T Induces Telomere Dysfunction and Inhibits Non-Canonical Telomerase Activity in Esophageal Carcinomas

BACKGROUND: Although implicated in the pathogenesis of several chronic inflammatory disorders and hematologic malignancies, telomerase mutations have not been thoroughly characterized in human cancers. The present study was performed to examine the frequency and potential clinical relevance of telom...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yuwei, Calado, Rodrigo, Rao, Mahadev, Hong, Julie A., Meeker, Alan K., Dumitriu, Bogdan, Atay, Scott, McCormick, Peter J., Garfield, Susan H., Wangsa, Danny, Padilla-Nash, Hesed M., Burkett, Sandra, Zhang, Mary, Kunst, Tricia F., Peterson, Nathan R., Xi, Sichuan, Inchauste, Suzanne, Altorki, Nasser K., Casson, Alan G., Beer, David G., Harris, Curtis C., Ried, Thomas, Young, Neal S., Schrump, David S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4077737/
https://www.ncbi.nlm.nih.gov/pubmed/24983628
http://dx.doi.org/10.1371/journal.pone.0101010
_version_ 1782323642861879296
author Zhang, Yuwei
Calado, Rodrigo
Rao, Mahadev
Hong, Julie A.
Meeker, Alan K.
Dumitriu, Bogdan
Atay, Scott
McCormick, Peter J.
Garfield, Susan H.
Wangsa, Danny
Padilla-Nash, Hesed M.
Burkett, Sandra
Zhang, Mary
Kunst, Tricia F.
Peterson, Nathan R.
Xi, Sichuan
Inchauste, Suzanne
Altorki, Nasser K.
Casson, Alan G.
Beer, David G.
Harris, Curtis C.
Ried, Thomas
Young, Neal S.
Schrump, David S.
author_facet Zhang, Yuwei
Calado, Rodrigo
Rao, Mahadev
Hong, Julie A.
Meeker, Alan K.
Dumitriu, Bogdan
Atay, Scott
McCormick, Peter J.
Garfield, Susan H.
Wangsa, Danny
Padilla-Nash, Hesed M.
Burkett, Sandra
Zhang, Mary
Kunst, Tricia F.
Peterson, Nathan R.
Xi, Sichuan
Inchauste, Suzanne
Altorki, Nasser K.
Casson, Alan G.
Beer, David G.
Harris, Curtis C.
Ried, Thomas
Young, Neal S.
Schrump, David S.
author_sort Zhang, Yuwei
collection PubMed
description BACKGROUND: Although implicated in the pathogenesis of several chronic inflammatory disorders and hematologic malignancies, telomerase mutations have not been thoroughly characterized in human cancers. The present study was performed to examine the frequency and potential clinical relevance of telomerase mutations in esophageal carcinomas. METHODS: Sequencing techniques were used to evaluate mutational status of telomerase reverse transcriptase (TERT) and telomerase RNA component (TERC) in neoplastic and adjacent normal mucosa from 143 esophageal cancer (EsC) patients. MTS, flow cytometry, time lapse microscopy, and murine xenograft techniques were used to assess proliferation, apoptosis, chemotaxis, and tumorigenicity of EsC cells expressing either wtTERT or TERT variants. Immunoprecipitation, immunoblot, immunofluorescence, promoter-reporter and qRT-PCR techniques were used to evaluate interactions of TERT and several TERT variants with BRG-1 and β-catenin, and to assess expression of cytoskeletal proteins, and cell signaling. Fluorescence in-situ hybridization and spectral karyotyping techniques were used to examine telomere length and chromosomal stability. RESULTS: Sequencing analysis revealed one deletion involving TERC (TERC del 341-360), and two non-synonymous TERT variants [A279T (2 homozygous, 9 heterozygous); A1062T (4 heterozygous)]. The minor allele frequency of the A279T variant was five-fold higher in EsC patients compared to healthy blood donors (p<0.01). Relative to wtTERT, A279T decreased telomere length, destabilized TERT-BRG-1-β-catenin complex, markedly depleted β-catenin, and down-regulated canonical Wnt signaling in cancer cells; these phenomena coincided with decreased proliferation, depletion of additional cytoskeletal proteins, impaired chemotaxis, increased chemosensitivity, and significantly decreased tumorigenicity of EsC cells. A279T expression significantly increased chromosomal aberrations in mouse embryonic fibroblasts (MEFs) following Zeocin™ exposure, as well as Li Fraumeni fibroblasts in the absence of pharmacologically-induced DNA damage. CONCLUSIONS: A279T induces telomere dysfunction and inhibits non-canonical telomerase activity in esophageal cancer cells. These findings warrant further analysis of A279T expression in esophageal cancers and premalignant esophageal lesions.
format Online
Article
Text
id pubmed-4077737
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-40777372014-07-03 Telomerase Variant A279T Induces Telomere Dysfunction and Inhibits Non-Canonical Telomerase Activity in Esophageal Carcinomas Zhang, Yuwei Calado, Rodrigo Rao, Mahadev Hong, Julie A. Meeker, Alan K. Dumitriu, Bogdan Atay, Scott McCormick, Peter J. Garfield, Susan H. Wangsa, Danny Padilla-Nash, Hesed M. Burkett, Sandra Zhang, Mary Kunst, Tricia F. Peterson, Nathan R. Xi, Sichuan Inchauste, Suzanne Altorki, Nasser K. Casson, Alan G. Beer, David G. Harris, Curtis C. Ried, Thomas Young, Neal S. Schrump, David S. PLoS One Research Article BACKGROUND: Although implicated in the pathogenesis of several chronic inflammatory disorders and hematologic malignancies, telomerase mutations have not been thoroughly characterized in human cancers. The present study was performed to examine the frequency and potential clinical relevance of telomerase mutations in esophageal carcinomas. METHODS: Sequencing techniques were used to evaluate mutational status of telomerase reverse transcriptase (TERT) and telomerase RNA component (TERC) in neoplastic and adjacent normal mucosa from 143 esophageal cancer (EsC) patients. MTS, flow cytometry, time lapse microscopy, and murine xenograft techniques were used to assess proliferation, apoptosis, chemotaxis, and tumorigenicity of EsC cells expressing either wtTERT or TERT variants. Immunoprecipitation, immunoblot, immunofluorescence, promoter-reporter and qRT-PCR techniques were used to evaluate interactions of TERT and several TERT variants with BRG-1 and β-catenin, and to assess expression of cytoskeletal proteins, and cell signaling. Fluorescence in-situ hybridization and spectral karyotyping techniques were used to examine telomere length and chromosomal stability. RESULTS: Sequencing analysis revealed one deletion involving TERC (TERC del 341-360), and two non-synonymous TERT variants [A279T (2 homozygous, 9 heterozygous); A1062T (4 heterozygous)]. The minor allele frequency of the A279T variant was five-fold higher in EsC patients compared to healthy blood donors (p<0.01). Relative to wtTERT, A279T decreased telomere length, destabilized TERT-BRG-1-β-catenin complex, markedly depleted β-catenin, and down-regulated canonical Wnt signaling in cancer cells; these phenomena coincided with decreased proliferation, depletion of additional cytoskeletal proteins, impaired chemotaxis, increased chemosensitivity, and significantly decreased tumorigenicity of EsC cells. A279T expression significantly increased chromosomal aberrations in mouse embryonic fibroblasts (MEFs) following Zeocin™ exposure, as well as Li Fraumeni fibroblasts in the absence of pharmacologically-induced DNA damage. CONCLUSIONS: A279T induces telomere dysfunction and inhibits non-canonical telomerase activity in esophageal cancer cells. These findings warrant further analysis of A279T expression in esophageal cancers and premalignant esophageal lesions. Public Library of Science 2014-07-01 /pmc/articles/PMC4077737/ /pubmed/24983628 http://dx.doi.org/10.1371/journal.pone.0101010 Text en https://creativecommons.org/publicdomain/zero/1.0/ This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration, which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.
spellingShingle Research Article
Zhang, Yuwei
Calado, Rodrigo
Rao, Mahadev
Hong, Julie A.
Meeker, Alan K.
Dumitriu, Bogdan
Atay, Scott
McCormick, Peter J.
Garfield, Susan H.
Wangsa, Danny
Padilla-Nash, Hesed M.
Burkett, Sandra
Zhang, Mary
Kunst, Tricia F.
Peterson, Nathan R.
Xi, Sichuan
Inchauste, Suzanne
Altorki, Nasser K.
Casson, Alan G.
Beer, David G.
Harris, Curtis C.
Ried, Thomas
Young, Neal S.
Schrump, David S.
Telomerase Variant A279T Induces Telomere Dysfunction and Inhibits Non-Canonical Telomerase Activity in Esophageal Carcinomas
title Telomerase Variant A279T Induces Telomere Dysfunction and Inhibits Non-Canonical Telomerase Activity in Esophageal Carcinomas
title_full Telomerase Variant A279T Induces Telomere Dysfunction and Inhibits Non-Canonical Telomerase Activity in Esophageal Carcinomas
title_fullStr Telomerase Variant A279T Induces Telomere Dysfunction and Inhibits Non-Canonical Telomerase Activity in Esophageal Carcinomas
title_full_unstemmed Telomerase Variant A279T Induces Telomere Dysfunction and Inhibits Non-Canonical Telomerase Activity in Esophageal Carcinomas
title_short Telomerase Variant A279T Induces Telomere Dysfunction and Inhibits Non-Canonical Telomerase Activity in Esophageal Carcinomas
title_sort telomerase variant a279t induces telomere dysfunction and inhibits non-canonical telomerase activity in esophageal carcinomas
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4077737/
https://www.ncbi.nlm.nih.gov/pubmed/24983628
http://dx.doi.org/10.1371/journal.pone.0101010
work_keys_str_mv AT zhangyuwei telomerasevarianta279tinducestelomeredysfunctionandinhibitsnoncanonicaltelomeraseactivityinesophagealcarcinomas
AT caladorodrigo telomerasevarianta279tinducestelomeredysfunctionandinhibitsnoncanonicaltelomeraseactivityinesophagealcarcinomas
AT raomahadev telomerasevarianta279tinducestelomeredysfunctionandinhibitsnoncanonicaltelomeraseactivityinesophagealcarcinomas
AT hongjuliea telomerasevarianta279tinducestelomeredysfunctionandinhibitsnoncanonicaltelomeraseactivityinesophagealcarcinomas
AT meekeralank telomerasevarianta279tinducestelomeredysfunctionandinhibitsnoncanonicaltelomeraseactivityinesophagealcarcinomas
AT dumitriubogdan telomerasevarianta279tinducestelomeredysfunctionandinhibitsnoncanonicaltelomeraseactivityinesophagealcarcinomas
AT atayscott telomerasevarianta279tinducestelomeredysfunctionandinhibitsnoncanonicaltelomeraseactivityinesophagealcarcinomas
AT mccormickpeterj telomerasevarianta279tinducestelomeredysfunctionandinhibitsnoncanonicaltelomeraseactivityinesophagealcarcinomas
AT garfieldsusanh telomerasevarianta279tinducestelomeredysfunctionandinhibitsnoncanonicaltelomeraseactivityinesophagealcarcinomas
AT wangsadanny telomerasevarianta279tinducestelomeredysfunctionandinhibitsnoncanonicaltelomeraseactivityinesophagealcarcinomas
AT padillanashhesedm telomerasevarianta279tinducestelomeredysfunctionandinhibitsnoncanonicaltelomeraseactivityinesophagealcarcinomas
AT burkettsandra telomerasevarianta279tinducestelomeredysfunctionandinhibitsnoncanonicaltelomeraseactivityinesophagealcarcinomas
AT zhangmary telomerasevarianta279tinducestelomeredysfunctionandinhibitsnoncanonicaltelomeraseactivityinesophagealcarcinomas
AT kunsttriciaf telomerasevarianta279tinducestelomeredysfunctionandinhibitsnoncanonicaltelomeraseactivityinesophagealcarcinomas
AT petersonnathanr telomerasevarianta279tinducestelomeredysfunctionandinhibitsnoncanonicaltelomeraseactivityinesophagealcarcinomas
AT xisichuan telomerasevarianta279tinducestelomeredysfunctionandinhibitsnoncanonicaltelomeraseactivityinesophagealcarcinomas
AT inchaustesuzanne telomerasevarianta279tinducestelomeredysfunctionandinhibitsnoncanonicaltelomeraseactivityinesophagealcarcinomas
AT altorkinasserk telomerasevarianta279tinducestelomeredysfunctionandinhibitsnoncanonicaltelomeraseactivityinesophagealcarcinomas
AT cassonalang telomerasevarianta279tinducestelomeredysfunctionandinhibitsnoncanonicaltelomeraseactivityinesophagealcarcinomas
AT beerdavidg telomerasevarianta279tinducestelomeredysfunctionandinhibitsnoncanonicaltelomeraseactivityinesophagealcarcinomas
AT harriscurtisc telomerasevarianta279tinducestelomeredysfunctionandinhibitsnoncanonicaltelomeraseactivityinesophagealcarcinomas
AT riedthomas telomerasevarianta279tinducestelomeredysfunctionandinhibitsnoncanonicaltelomeraseactivityinesophagealcarcinomas
AT youngneals telomerasevarianta279tinducestelomeredysfunctionandinhibitsnoncanonicaltelomeraseactivityinesophagealcarcinomas
AT schrumpdavids telomerasevarianta279tinducestelomeredysfunctionandinhibitsnoncanonicaltelomeraseactivityinesophagealcarcinomas